NCT06679374招募中2 期
Reducing Falls With Varenicline in Hypocholinergic Parkinson Disease
Vikas Kotagal1 个研究点 分布在 1 个国家目标入组 102 人开始时间: 2025年4月9日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 102
- 试验地点
- 1
- 主要终点
- Change in normal pace-dual task cost (npDTC) from baseline to 12 months.
研究概览
简要总结
This trial aims to test whether one year of Varenicline, when compared to placebo, can reduce fall risk and show improvement in the ability to multitask while walking.
Participants that are eligible after screening for the study will be randomized to receive Varenicline or placebo. Along with the study medication participants will have visits (over the phone and in person), various tests and imaging, questionnaires, and laboratory collections.
详细描述
The hypothesis of the trial are:
- The primary hypothesis is that varenicline will result in less progress in dual-task cost gait performance after 12 months of treatment compared to placebo in hypocholinergic Parkinson disease (PD) Mild Cognitive Impairment (MCI) patients.
- The primary secondary hypothesis assesses whether the magnitude of effect of varenicline relative to placebo is consistent with the minimal clinically important difference (MCID) for the relative risk of falls in the 12-month double-blind treatment period.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
盲法说明
This is a double-blind study. The study personnel (except for select staff at the Data Coordinating Center (DCC) and research pharmacy).
入排标准
- 年龄范围
- 45 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participants with a PD diagnosis based on the Movement Disorders Society Clinical Diagnostic Criteria for Parkinson's Disease at the time of baseline screening/enrollment visit
- •Participants with occipital association cortex cholinergic denervation in the lowest tertile of the normal range on F-fluoroethoxybenzovesamicol (FEOBV) Positron Emission Tomography (PET)
- •Participants with legally authorized representatives (LARs) able to co-sign documented informed consent or participants that have capacity to provide informed consent upon study enrollment as ascertained by the study-specific University of California, San Diego Brief Assessment of Capacity to Consent (UBACC)
- •Mild Cognitive Impairment consistent with Parkinson disease Mild Cognitive Impairment (PD-MCI)
排除标准
- •Atypical Parkinsonian conditions other than Parkinson disease (PD)
- •Participants initially on certain dopamine blocking drugs (per protocol), specific anticholinergic drugs (trihexyphenidyl, benztropine), or specific cholinesterase inhibitor drugs (per protocol) at the in-person screening visit
- •Modified Hoehn and Yahr score of 4.0 or greater at the in-person screening visit
- •Current or previous (within last 6 months of in-person screening visit) use of any product or medication containing nicotinic agents, including use of tobacco products such as cigarettes, cigars, pipes, chewing tobacco, etc., e-cigarettes, over the counter (OTC) nicotine patches, chewing gum containing nicotine, or varenicline
- •Evidence of a stroke with both cortical and subcortical involvement or occipital lobe mass lesion on structural magnetic brain imaging (MRI) obtained at the in-person screening visit that would preclude co-registration and analysis of FEOBV PET data
- •Participants where magnetic resonance imaging (MRI) is contraindicated including, but not limited to, those with a pacemaker, presence of metallic fragments near the eyes or spinal cord, or cochlear implant
- •Severe claustrophobia precluding MRI or PET imaging
- •Participants limited by participation in research procedures involving ionizing radiation
- •Pregnancy (test within 48 hours of the PET imaging session in women of childbearing potential) or breastfeeding at the time of in-person screening visit
- •Participants with stage 4 or 5 chronic kidney disease at the time of in-person screening visit (estimated Creatinine Clearance < 30 milliliters per minute)
- •Current, significant mood disorder at the time of in-person screening/enrollment visit defined as follows: persistent (lasting longer than 2 weeks) symptoms of depression or anxiety in the 30 days preceding informed consent, as determined by self-report
- •Evidence of active suicidal ideation as defined by an affirmative answer to either question 1 or 2 on the Columbia Suicide Severity Rating Scale (C-SSRS)
- •History of a myocardial infarction or unstable angina in the 90 days preceding enrollment visit
- •A current or previous history of epilepsy or any epileptic seizures in the 12 months preceding enrollment
- •Heavy alcohol use as defined by a score of 8 or greater on the Alcohol Use Disorders Identification Test (AUDIT-self-report version) at the time of screening/enrollment visit
- •Participants that are unable to swallow pills
- •Participants with a history of allergic reaction to varenicline
- •Participants that are actively taking part in another ongoing interventional (i.e., not observational) clinical trial
研究组 & 干预措施
Placebo
Placebo Comparator
干预措施: Placebo (Drug)
Varenicline
Experimental
干预措施: Varenicline (Drug)
结局指标
主要结局
Change in normal pace-dual task cost (npDTC) from baseline to 12 months.
时间窗: Baseline, 12 months
Normal pace-dual task cost is defined as the within-subject difference between normal pace walking speed without dual tasking to normal pace walking speed with dual tasking divided by normal pace walking speed without dual tasking, multiplied by 100.
次要结局
- Number of falls from the first dose of study drug to the 12-month visit(First dose (day 0) to 12 month visit)
研究者
Vikas Kotagal
Associate Professor of Neurology
University of Michigan
研究点 (1)
Loading locations...
相似试验
已完成
4 期
Varenicline Light Smoking PilotSmoking CessationSmoking BehaviorsSmokingNCT04089982Duke University11
已完成
2 期
Varenicline for Alcohol DependenceAlcoholismNCT01146613National Institute on Alcohol Abuse and Alcoholism (NIAAA)200
已完成
2 期
Cholinergic Mechanisms of Gait Dysfunction in Parkinson's Disease Experiments 1 & 2 - Proj #3Parkinson's DiseaseNCT02933372University of Michigan25
已完成
3 期
Efficacy and Safety of Varenicline in Smokers With Cardiovascular Disease Who Wish to Quit SmokingSmoking CessationNCT00282984Pfizer714
已完成
3 期
A Twelve-Week Study of Varenicline for Safety and Efficacy in Comparison With Placebo and Zyban for Smoking CessationSmoking CessationNCT00141206Pfizer1,005